IND227 phase III study of cisplatin/pemetrexed with or without pembrolizumab in patients with malignant pleural mesothelioma
Dr. Brandao, a medical oncologist at Hôpital Universitaire de Bruxelles, Institut Jules Bordet, delved into the findings of this phase III study involving the use of chemotherapy (cisplatin and pemetrexed) and immunotherapy (pembrolizumab) as a first-line treatment for malignant pleural mesothelioma. In addition to her analysis of the results, Dr. Brandao contextualizes them within the Belgian healthcare system.
With the educational support of:
